A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy.

Trial Profile

A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Acute myeloid leukaemia vaccine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 May 2016 Status changed from active, no longer recruiting to completed.
    • 24 Aug 2015 Planned End Date changed from 1 Sep 2018 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 24 Aug 2015 Planned primary completion date changed from 1 Sep 2018 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top